CDF to save NHS £140m over five years

The Cancer Drugs Fund (CDF) is expected to save the U.K. National Health Service (NHS) a minimum of £140 million over the next five years. Medicines that are recommended to the CDF by NICE (National Institute of Health and Care Excellence) have their prices negotiated lower than the manufacturer’s initial listed price. Over 15,000 patients […]

Read More


Cancer treatments: A brief history

February 4 was World Cancer Day and here at Partners4Access, we are having a look back at how cancer treatments have evolved through the years and where they are likely to go in the future. First came surgery In the 18th century, surgery was hailed as the first effective cancer treatment. The discovery of anesthesia […]

Read More


Though there is some way to go, NICE is moving in the right direction on HTAs

  From 1 March 2000 to 31 December 2017, NICE (National Institute for Health and Care Excellence) published over 800 healthcare technology recommendations. In total, 81% of those decisions were recommended, optimized or recommended for use in the Cancer Drugs Fund (CDF). Why then is NICE considered such a tough cookie when it comes to […]

Read More


Orphan Drug Pricing: Is Eurordis call to reduce prices by 3-5 times the answer to unequitable access?

Partners4Access comments on the new Eurordis Position Paper Earlier this month Eurordis published its position paper on orphan drug access. Whilst the report is commendable in pushing to drive equitable access for patients; their call to reduce orphan drug prices by 3 to 5 times by 2025 is no guarantee of full patient access. Affordability […]

Read More


European P&MA Consolidation: A Paradigm Shift and Implications for Pharma

Earlier this month, Italy’s Health Minister, Beatrice Lorenzin, announced that two additional countries- Slovenia and Croatia- had signed up to the Valletta Declaration. Of the 28 EU member states, over a third (10 countries*) are now part of the initiative which aims to strengthen their bargaining power over pharmaceutical companies through collective price negotiations and […]

Read More


Hot topics in pharma and orphan drugs

I attended this year’s pharma pricing and market access conference in London with attendees across the pharmaceutical industry, payer and HTA bodies and patient representatives. While following the talks, panel discussions and roundtable debates, a few overarching key topics crystallised: –          Germany – AMNOG changes AMNOG, the German pharmaceutical law is regularly adapted to changes […]

Read More


AMNOG and the German Reforms: What Will Change?

Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial opportunities and has an important position as an international reference country to 17 markets. The implementation of AMNOG in 2011 sought to reduce drug prices and relieve the healthcare budget, yet financial pressure remains, particularly […]

Read More

All Rights Reserved ©   Privacy   Partners 4 Access 2018